Inotek Pharmaceuticals (NSDQ:ITEK) said last week that its glaucoma drug failed in a Phase II trial. This marks the 2nd problem for Inotek’s drug this year, after it failed in a late-stage trial comparing it to a placebo in January.
In response to the data, CEO David Southwell said in a statement that the company is assessing the future of its drug, trabodenoson, and “other strategic options.”
Get the full story at our sister site, Drug Delivery Business News.
The post Inotek recalibrates after drug fails in glaucoma trial appeared first on MassDevice.